SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Betteridge ZE, Gunawardena H, McHugh NJ.Novel autoantibodies and clinical phenotypes in adult and juvenile myositis.Arthritis Res Ther2011;13:209.
  • 2
    Casciola-Rosen L, Mammen AL.Myositis autoantibodies.Curr Opin Rheumatol2012;24:6028.
  • 3
    Madan V, Chinoy H, Griffiths CE, Cooper RG.Defining cancer risk in dermatomyositis: part I.Clin Exp Dermatol2009;34:4515.
  • 4
    Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al.Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.Arthritis Rheum2012;64:51322.
  • 5
    Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al, for the Juvenile Dermatomyositis Research Group, UK and Ireland.Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.Arthritis Rheum2009;60:180714.
  • 6
    Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al.The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.Rheumatology (Oxford)2010;49:43340.
  • 7
    Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al.RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease.Arthritis Rheum2009;60:2193200.
  • 8
    Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW.Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract].Arthritis Rheum2006;54 Suppl:S518.
  • 9
    Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV.Sera with autoantibodies to the MJ antigen react with NXP2 [abstract].Arthritis Rheum2007;56 Suppl:S787.
  • 10
    Chen F, Wang D, Shu X, Nakashima R, Wang G.Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis.Rheumatol Int2012;32:390915.
  • 11
    Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L.The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.J Am Acad Dermatol2011;65:2534.
  • 12
    Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al.Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study.Arch Dermatol2011;147:3918.
  • 13
    Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T.Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.Rheumatology (Oxford)2010;49:172633.
  • 14
    Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al.Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.Arthritis Rheum2005;52:15716.
  • 15
    Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al.Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum.Arthritis Care Res (Hoboken)2013. E-pub ahead of print.
  • 16
    Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al.Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis.Arthritis Rheum2012;64:52332.
  • 17
    Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z.Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients.J Dermatol2011;38:9739.
  • 18
    Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al.Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.BMC Musculoskelet Disord2010;11:223.
  • 19
    Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG.The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.Ann Rheum Dis2007;66:13459.
  • 20
    Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups.A novel autoantibody to a 155-kd protein is associated with dermatomyositis.Arthritis Rheum2006;54:36829.
  • 21
    Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al, and for the Juvenile Dermatomyositis Research Group UK.Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis.Rheumatology (Oxford)2008;47:3248.
  • 22
    Betteridge ZE, Gunawardena H, Chinoy H, Vencovsky J, Allard S, Gordon PA, et al.Autoantibodies to the p140 autoantigen NXP-2 in adult dermatomyositis [abstract].Arthritis Rheum2009;60 Suppl:S304.
  • 23
    Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al.Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis.Arthritis Res Ther2012;14:R97.
  • 24
    Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al.Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.Ann Rheum Dis2012;71:7103.
  • 25
    Ishikawa A, Muro Y, Sugiura K, Akiyama M.Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.Rheumatology (Oxford)2012;51:11817.
  • 26
    Espada G, Maldonado Cocco JA, Fertig N, Oddis CV.Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein.J Rheumatol2009;36:254751.
  • 27
    Bohan A, Peter JB.Polymyositis and dermatomyositis (first of two parts).N Engl J Med1975;292:3447.
  • 28
    Sontheimer RD.Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects.Dermatol Clin2002;20:387408.
  • 29
    Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL.Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.Medicine (Baltimore)2005;84:23149.
  • 30
    Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD.A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.J Am Acad Dermatol2006;54:597613.
  • 31
    Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Tincani A, et al.Anti-MJ/NXP-2 antibodies are the most common specificity in a cohort of adult Caucasian patients with dermatomyositis [abstract].Arthritis Rheum2011;63 Suppl:S856.
  • 32
    Fiorentino D, Callen JP. Dermatomyositis. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, editors.Evidence-based dermatology.Oxford:Blackwell Publishing;2008. p.55972.
  • 33
    Bendewald MJ, Wetter DA, Li X, Davis MD.Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.Arch Dermatol2010;146:2630.